ELVN Enliven Therapeutics Forecast, Technical & Fundamental Analysis
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics... Show more
ELVN is expected to report earnings to rise 13.42% to -43 cents per share on November 18
Q3'26
Est.
$-0.43
Q1'26
Beat
by $0.06
Q4'25
Missed
by $0.02
Q3'25
Beat
by $0.18
Q2'25
Beat
by $0.06
The last earnings report on May 07 showed earnings per share of -37 cents, beating the estimate of -44 cents. With 495.66K shares outstanding, the current market capitalization sits at 4.37B.
A.I.dvisor indicates that over the last year, ELVN has been loosely correlated with MLTX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ELVN jumps, then MLTX could also see price increases.
ELVN sees MACD Histogram crosses below signal line
ELVN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 57 instances where the indicator turned negative. In of the 57 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ELVN moved out of overbought territory on August 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ELVN as a result. In of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELVN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ELVN broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 69 cases where ELVN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ELVN advanced for three days, in of 272 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 161 cases where ELVN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ELVN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.883) is normal, around the industry mean (20.583). P/E Ratio (0.000) is within average values for comparable stocks, (27.923). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.559). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.835).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
